CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker

CervoMed Inc.

In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.
Neflamapimod reduced the risk of clinically meaningful progression by 75% vs placebo over 16 weeks (p<0.001).
Plasma GFAP levels decreased by median -23.1 pg/mL on neflamapimod vs +5.8 on placebo (p=0.016); GFAP change correlated with CDR-SB.
FDA feedback on Phase 3 trial design expected in Q4 2025.
Two drug capsule batches were used; only the newer batch (NFMD/B) achieved target plasma concentrations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.